Jump to content
Content on WikiMesothelioma is reviewed prior to publication by three named attorneys at Danziger & De Llano LLP. Dr. Luciano Mutti, MD, PhD, co-author of the European mesothelioma treatment guidelines, serves as the site's Medical Reviewer. See our editorial standards.

Mesothelioma Prognosis

From WikiMesothelioma — Mesothelioma Knowledge Base
Mesothelioma Prognosis
Individual Prognostic Factors & Scoring Systems
Median OS (First-Line Trial) 18.1 months nivolumab + ipilimumab; 14.1 months chemotherapy (CheckMate 743)[1]
Germline BAP1 Carrier Median OS 5 years
Best Scoring System PLECH (AUC 0.70)
Median Survival, Ages 18–44 59 months
Female 5-Year Survival 13.4% vs. 4.5% male
Key Prognostic Factors Stage, histology, PS, age, germline BAP1, NLR

Executive Summary

Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level survival statistics.[2] Across 41,074 U.S. patients in the National Cancer Database (2004–2020), median overall survival for pleural mesothelioma was 10.3 months from diagnosis.[3] Individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.[4][5] Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.[6][7] Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.[8]

At a Glance

  • Median survival is about 10 months from diagnosis — 10.3 months across 41,074 U.S. patients in the National Cancer Database, 2004–2020, but individual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers[3]
  • Germline BAP1 mutation carriers survive 7 times longer — median 5 years compared to less than 1 year for unselected SEER population controls; the same advantage is not established for somatic BAP1 loss[5][9]
  • Epithelioid subtype doubles survival — 14–18 months median versus 4–8 months for sarcomatoid, with 5-year rates of 14% versus 4%
  • Women survive nearly 3 times longer — 13.4% five-year survival versus 4.5% for men, with 22% reduced mortality risk (HR 0.78)
  • Younger patients live longer — median survival of 59 months for ages 18–44 versus 10 months for those 75 and older[10]
  • PLECH score (2025) predicts survival most accurately — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
  • Elevated NLR signals significantly higher mortality — one-year survival drops substantially when this simple blood test ratio is high
  • Peritoneal patients with complete surgery survive 8.7 years — median 104 months after cytoreductive surgery with HIPEC in a single-centre Australian series of 81 patients
  • High-volume centers reduce surgical death by 31% — 10.0% versus 14.6% ninety-day mortality at specialized facilities

Key Facts

Key Facts: Mesothelioma Prognosis
  • Median Overall Survival: 10.3 months from diagnosis in the U.S. National Cancer Database (41,074 patients, 2004–2020)[3]; 7 months in a SEER study of 14,228 patients[4]
  • Germline BAP1 Mutation Carriers: 7-fold improved long-term survival with median of 5 years versus less than 1 year for unselected SEER population controls[5]
  • Epithelioid vs. Sarcomatoid: 14–18 months vs. 4–8 months median survival; epithelioid 5-year survival approximately 14% vs. 4% for sarcomatoid[11][12]
  • Gender Difference: Women show HR 0.78 (22% reduced mortality risk) with 5-year survival of 13.4% vs. 4.5% for men[13]
  • Age Effect: Median survival of 59 months for patients aged 18–44 versus 10 months for those 75 and older, in a U.S. cohort of 888 patients[10]
  • PLECH Score (2025): AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57)[6]
  • NLR Biomarker: Elevated neutrophil-to-lymphocyte ratio is associated with significantly reduced survival[14]
  • Peritoneal with CC-0: Complete cytoreduction achieved median 104 months (8.7 years) survival in a single-centre Australian series of 81 patients[15]
  • Performance Status: Poor performance status independently predicted shorter survival in the EORTC analysis,[7] remained significant on multivariate analysis in the PLECH cohort[6] and was the most important split in the CALGB model[16]
  • Specialized Centers: High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery[17]

What Does "Median Survival" Mean for One Patient?

Almost every mesothelioma survival figure is a median: the point at which half of a group had died and half were still alive. It is not a deadline and it is not a prediction for any one person. When the National Cancer Database reports a median of 10.3 months for pleural mesothelioma, it means half of those 41,074 patients lived longer than 10.3 months and half did not.[3]

Two other measures appear in the literature. A five-year survival rate is the share of a group still alive five years after diagnosis or treatment began. Conditional survival asks a different question: for patients who have already lived a given length of time, how much longer do they typically live? That second number is often the more useful one for a family a year or more past diagnosis. In a single-center series of 111 peritoneal mesothelioma patients treated with CRS-HIPEC, median overall survival was 3.3 years for the whole group, but patients who reached one year after surgery had a median conditional survival of 4.9 years, and those who reached three years had a median conditional survival of 6.1 years.[18]

The spread around a median can be wide. In that same series, a quarter of patients lived less than 10.7 months and a quarter lived more than 10.6 years.[18] A median describes the middle of a distribution. It says little about its edges, which is where many individual patients end up.

A longer life expectancy is not the same as a normal one. An analysis of 10,258 pleural and 1,229 peritoneal patients in the SEER national cancer database from 1973 to 2011 concluded that life expectancies were "markedly reduced from normal, even amongst 5-year survivors with the most favorable characteristics and treatment options".[19] Families planning for care, work, and legal deadlines should read survival statistics with both facts in view.

Why Do Survival Numbers Differ So Much Between Sources?

The single largest reason two mesothelioma survival figures disagree is who was counted. Population registries count everyone diagnosed, including patients too sick for treatment. Clinical trials count only patients who met strict entry criteria, usually good performance status and no disqualifying illness. Surgical series count only patients a surgeon judged fit for an operation.

The registry numbers cluster tightly. The U.S. National Cancer Database reports a median of 10.3 months (2004–2020).[3] The Dutch cancer registry reports 9.3 months for 2012–2018 (pleural and peritoneal mesothelioma combined), and in the Dutch data the most common reasons patients received no anti-tumour treatment were patient preference (42%) and performance status (25.6%).[20]

In SEER-Medicare, whose patients had a median age of 78 at diagnosis, median overall survival was 8 months for 2005–2009 (pleural and peritoneal combined).[21]

Trial populations look different by design. CheckMate 743 enrolled only adults with an Eastern Cooperative Oncology Group performance status of 0 or 1.[1] Its chemotherapy arm had a median overall survival of 14.1 months.[1] Each registry median below is lower:

  • 10.3 months in the National Cancer Database, 2004–2020[3]
  • 9.3 months in the Netherlands for 2012–2018, and 7.3 months for 1993–2003, pleural and peritoneal combined[20]
  • 8 months in SEER-Medicare, 2005–2009, pleural and peritoneal combined[21]

Part of that gap is who was enrolled, not only which treatment they received.

Surgical series are the most selected of all. The peritoneal CRS-HIPEC series cited in this section come from referral centers that chose patients for major surgery.[22][18] In the Alexander series, younger age, near-complete resection, low histologic grade, and cisplatin-based HIPEC were each independently associated with longer survival.[22] Age and tumor grade describe the patient, not the operation, which is one reason surgical series cannot be read as the effect of surgery alone.

The practical rule: compare a trial number only with its own control arm, and compare a registry number only with another registry number. Mixing the two, for example setting a trial arm against a population median, inflates any apparent treatment benefit.

How Has Treatment Changed Life Expectancy?

Pleural mesothelioma survival has improved, but slowly. SEER data from 1973 to 2011 show survival gains of about 0.5% per year for pleural and 2% per year for peritoneal mesothelioma.[19] In the Netherlands, the population median for pleural and peritoneal mesothelioma combined rose from 7.3 to 9.3 months across three periods between 1993 and 2018, alongside a rise in systemic chemotherapy for pleural disease from 9.3% to 39.4% of patients.[20]

Chemotherapy (2003)

The phase III trial that established pemetrexed plus cisplatin as the chemotherapy standard reported a median survival of 12.1 months, against 9.3 months with cisplatin alone, a hazard ratio of 0.77.[23]

Immunotherapy (2020 onward)

CheckMate 743 randomized 605 patients with unresectable pleural mesothelioma to nivolumab plus ipilimumab or platinum-pemetrexed chemotherapy. Median overall survival was 18.1 months against 14.1 months (hazard ratio 0.74), and two-year survival was 41% against 27%.[1] With a minimum of three years' follow-up, three-year survival was 23% against 15%.[24] With a median follow-up of 66.8 months, five-year survival was 14% against 6%, with a hazard ratio of 0.74, and the authors reported similar benefit regardless of tumor histology.[25] The U.S. Food and Drug Administration's approval of the combination for unresectable pleural mesothelioma rested on this trial.[26]

Tumor Treating Fields

The single-arm phase 2 STELLAR trial combined Tumor Treating Fields with pemetrexed and platinum chemotherapy in 80 patients and reported a median overall survival of 18.2 months.[27] STELLAR had no randomized control arm, so its 18.2 months cannot be set against CheckMate 743's 18.1 months as if the two were measured the same way.

For current treatment options and trials, see Mesothelioma Treatment.

What Factors Determine Mesothelioma Prognosis?

Mesothelioma prognosis is shaped by a combination of disease-related, patient-related, and treatment-related factors.[28] Unlike many cancers where staging alone drives prognosis, mesothelioma outcomes depend on a broader constellation of variables that clinicians assess collectively.

Disease-Related Factors include the anatomic site (pleural, peritoneal, pericardial, or testicular), histologic subtype (epithelioid, sarcomatoid, or biphasic), disease stage at diagnosis, and molecular characteristics such as BAP1 mutation status.[29][30] Peritoneal mesothelioma carries a fundamentally different prognosis than pleural disease, particularly when treated with cytoreductive surgery and HIPEC.[31]

Patient-Related Factors encompass performance status (ECOG score), age at diagnosis, gender, nutritional status (serum albumin), and laboratory values including hemoglobin, white blood cell count, platelet count, lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR).[6][32] These measurable values form the basis of validated prognostic scoring systems.

Treatment-Related Factors include whether multimodal therapy is pursued, the completeness of surgical resection, access to state-of-the-art therapeutic approaches, enrollment in clinical trials, and treatment at a high-volume specialized center.[33][34] Patients who receive treatment at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes.[35]

ℹ Note: Prognosis is a statistical estimate based on groups of patients with similar characteristics — it does not predict what will happen to any individual. Some patients significantly outlive their predicted prognosis, particularly those with favorable molecular profiles such as germline BAP1 mutations.

How Do Prognostic Scoring Systems Predict Outcomes?

Four validated prognostic scoring systems have been developed specifically for mesothelioma, each combining multiple clinical variables to stratify patients into risk groups.[6][7] These tools help oncologists set treatment expectations and guide decision-making about aggressive versus palliative approaches.

EORTC Prognostic Score (1998)

The European Organisation for Research and Treatment of Cancer score was the first validated mesothelioma prognostic model, developed from 204 patients across 5 phase II trials between 1984 and 1993.[7]

Variables: Poor performance status, high white blood cell count, probable or possible histologic diagnosis, male gender, and sarcomatous histology.[7]

Prognostic Group Criteria 1-Year Survival
Good prognosis 2 or fewer of the 5 factors 40% (95% CI: 30–50%)
Poor prognosis 3 or more of the 5 factors 12% (95% CI: 4–20%)

The EORTC model was validated at St Bartholomew's Hospital in 145 patients treated in sequential phase II chemotherapy trials; among the 70 treated with vinorelbine, median survival was 19.2 months in the best EORTC prognostic group versus 9.9 months in the worst.[36] However, in contemporary analyses, its discriminatory power is limited (AUC 0.57).[6]

CALGB Prognostic Score (1998)

The Cancer and Leukemia Group B score was developed from 337 patients accrued to seven CALGB phase II studies between 1984 and 1994. Cox models and regression trees formed six prognostic subgroups; performance status was the most important split, and pleural involvement, LDH above 500 IU/L, chest pain, platelet count above 400,000/µL, non-epithelial histology and age over 75 jointly predicted poor survival.[16]

The CALGB score was validated in a Leicester series (n=142) with results equivalent to the original data. Current AUC for 1-year overall survival prediction: 0.60.[6]

Brims Decision Tree Model (2016)

Developed from 482 cases with 174-case external validation (2005–2014), the Brims model uses a decision tree approach with five variables: weight loss, hemoglobin, serum albumin, performance status, and histology.[32][37]

Risk Group 18-Month Survival Median Survival Characteristics
Group 1 (best) 86.7% 34.0 months No weight loss, Hb >153 g/L, albumin >43 g/L
Group 2 Intermediate Intermediate No weight loss, not meeting Group 1 lab criteria
Group 3 Intermediate Intermediate Weight loss present, PS 0–1, epithelioid histology
Group 4 (worst) 0% 7.5 months Weight loss present, PS 0–1, sarcomatoid histology

The Brims model achieved a C-statistic of 0.761 (derivation) and 0.68 (validation) with 94.5% sensitivity. The British Thoracic Society endorses it as a clinical tool to consider at diagnosis.[37][32]

PLECH Score (2025)

The newest and most accurate prognostic model, PLECH was developed from 262 patients at two cancer centers (2010–2023). Its name reflects the five weighted variables:[6]

  • Platelet count (high): +2 points
  • LDH (high): +1 point
  • ECOG ≥2: +1 point
  • Chest pain at diagnosis: +2 points
  • Non-epithelioid Histology: +1 point

Score range: 0–7 points. Optimal cut-off: 2.5.[6]

Risk Group Median OS Median PFS
Low risk (score <3) 20.1 months 11.3 months
High risk (score ≥3) 12.3 months 6.4 months

The PLECH score achieved an AUC of 0.70 for 1-year overall survival prediction, outperforming both CALGB (0.60) and EORTC (0.57) in the same patient population.[6]

"We advocate for early case evaluation because prognostic data directly informs legal strategy. A patient's scoring system results and biomarker profile shape not only treatment planning but also the urgency of filing claims before applicable deadlines expire."
— Paul Danziger, Founding Partner, Danziger & De Llano

How Does ECOG Performance Status Predict Outcomes?

The Eastern Cooperative Oncology Group (ECOG) Performance Status scale is a clinician-rated measure of functional capacity. In a retrospective series of peritoneal mesothelioma treated with cytoreductive surgery, ECOG score was an independent prognostic factor on multivariate analysis.[38] For pleural mesothelioma, the 2025 ASCO guideline states that selected patients with a poor performance status (PS 2) may be offered single-agent palliative chemotherapy or palliative care alone, and that patients with a PS of 3 or greater should receive palliative care.[39]

A retrospective analysis of 44 malignant peritoneal mesothelioma patients treated with cytoreductive surgery found ECOG score to be an independent prognostic factor on multivariate analysis, alongside TNM stage and treatment modality.[38]

The pivotal CheckMate 743 trial shows how tightly performance status gates access to first-line treatment. Enrollment was restricted to ECOG PS 0 or 1; patients at PS 2 or worse were not studied, so the regimen's effect in that group is unknown rather than established.[1]

The trial reported median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy, and the five-year update published in 2026 reported five-year overall survival of 14% versus 6% (HR 0.74; 95% CI 0.62–0.88).[1][25] An early reading of the interim analysis suggested the benefit was concentrated in non-epithelioid disease; both the three-year and five-year updates superseded that, reporting benefit consistent across histologic subgroups.[24][25] The five-year analysis has itself been challenged in the same journal on methodological grounds, in a letter arguing that the reported difference is fragile and affected by censoring.[40] These figures describe a trial population selected for good performance status and should not be read as expected outcomes for patients who would not have met those criteria.

Performance status is also embedded in every validated mesothelioma prognostic scoring system. The PLECH score assigns a +1 point penalty for ECOG ≥2; the EORTC and CALGB scores both include performance status as a core variable; and Danish clinical guidelines published in 2025 explicitly limit surgical eligibility to patients with ECOG PS 0–1, age below 75, preserved cardiac and pulmonary function, Stage I–IIIA disease, and epithelioid or low-sarcomatoid biphasic histology.[41][6]

What Role Do Blood Markers Play in Prognosis?

Several routine laboratory values serve as independent prognostic indicators in mesothelioma, many of which are incorporated into the scoring systems described above.[6][32]

Biomarker Direction Impact Evidence
Neutrophil-to-Lymphocyte Ratio (NLR) Elevated NLR = worse Elevated HR; significantly reduced 1-year survival Meta-analysis[14]
Platelet Count High = worse +2 points in PLECH score (highest weight) PLECH 2025[6]
LDH (Lactate Dehydrogenase) High = worse Independent predictor; +1 in PLECH PLECH 2025, CALGB[6][42]
Hemoglobin Normal/high = better Hb >153 g/L associated with Group 1 (best) prognosis Brims 2016, EORTC[32][7]
Serum Albumin High = better Albumin >43 g/L associated with best prognostic group Brims 2016[32]
White Blood Cell Count High = worse Leukocytosis independently predicts poor outcome EORTC, SEER[7][4]

These biomarkers are particularly valuable because they are measured through routine blood tests available at any medical facility and can be monitored throughout treatment to track disease trajectory.[43]

How Do Germline BAP1 Mutations Affect Long-Term Survival?

Germline BAP1 (BRCA1-associated protein 1) mutations are the most significant molecular prognostic factor identified in mesothelioma.[5][44] The distinction between germline and somatic BAP1 alteration is essential and is often blurred. An inherited germline mutation is present in every cell of the body and is associated with markedly better survival. Somatic BAP1 loss occurs only in tumour tissue and is the single most common genetic alteration in sporadic mesothelioma, but a 2025 review concluded that the better prognosis seen in germline carriers "is not observed in those with somatic mutations," and that BAP1 is "not yet suitable for use in clinical practice as a prognostic or predictive factor" on the basis of somatic status.[9] Everything that follows in this section describes germline mutation carriers.

In a landmark study comparing 23 mesothelioma patients with germline BAP1 mutations to 10,556 SEER controls:[5]

  • Actuarial median survival: 5 years (versus less than 1 year for SEER controls)
  • 5-year survival: 47% (95% CI: 24–67%) versus 6.7% (6.2–7.3%) in SEER
  • 7-fold improved long-term survival, independent of sex and age
  • Peritoneal BAP1 carriers: Median survival of 10 years
  • Carriers with second malignancy: Median survival of 10 years

BAP1 carriers tend to develop epithelioid histology, respond exceptionally well to platinum-based chemotherapy, and demonstrate significantly enhanced chemosensitivity compared to sporadic mesothelioma cases.[45][46]

Is germline BAP1 mesothelioma a different disease?

Series published in 2025 indicate the survival difference is not simply a better outcome from the same cancer. In a study of 47 families and 238 germline BAP1 carriers, 84 of whom developed mesothelioma, the tumours arising in carriers differed "biologically, histologically, and clinically" from sporadic mesothelioma.[47] The authors describe tumours that remain indolent for years and propose the term low-grade germline-mutant-BAP1-associated mesothelioma (L-BAM) to distinguish them from aggressive, therapy-resistant sporadic disease.[47]

At an early stage these patients did not require aggressive therapy. Among roughly one third whose disease became visible on imaging, surgery, chemotherapy, or a combination produced survival of several years and some patients were cured; deep invasion with a solid architecture was rare and carried poor survival.[47] This has practical consequences: a finding that would be read as advanced disease in sporadic mesothelioma may describe an indolent tumour in a known germline carrier, and treatment intensity is calibrated differently as a result.[47]

In this cohort mesothelioma occurred in 84 of 238 carriers (35%) and in none of 123 siblings and first- or second-degree relatives who did not inherit the mutation (p < 0.0001); 1 of the 84 had evidence of asbestos exposure.[47] These are observed features of a group recruited specifically for an inherited cancer-predisposition syndrome, in which carriers are a small minority of all mesothelioma patients. They characterise that population and do not speak to the cause of any individual case.[47][48]

✓ Germline BAP1 and surveillance: Clinical practice guidelines (2023) recommend genetic counseling and surveillance for people carrying germline BAP1 mutations.[48] The form that surveillance should take is unsettled. In a prospective National Cancer Institute protocol, 50 carriers underwent CT imaging followed by thoracoscopy and laparoscopy; mesothelioma was identified in 39 of 45 surgically evaluated subjects, and the investigators reported that "CT scans were unreliable for detecting or ruling out these mesotheliomas."[49] Imaging alone should not be treated as sufficient to exclude disease in a known carrier.

A 2022 review by leading researchers noted that a fraction of BAP1 carrier patients "actually live 10 to 20 years and probably will not die of mesothelioma."[46] This represents a fundamentally different disease biology with implications for treatment intensity, surveillance strategy, and long-term planning.

What Factors Can Improve a Patient's Prognosis?

While mesothelioma prognosis depends partly on immutable factors like age and gender, several modifiable factors can meaningfully influence outcomes:[34][50]

Early-Stage Diagnosis: Stage I patients have 5-year survival of 33% versus 4% for Stage IV. Localized disease at SEER summary staging achieves 23% five-year relative survival.[51][30]

Treatment at a Specialized Center: A National Cancer Database analysis (n=1,307) demonstrated that high-volume facilities achieve lower 30-day readmission rates (4.6% vs. 6.1%, p=0.021) and lower 90-day mortality (10.0% vs. 14.6%, p=0.029) compared to lower-volume centers.[17][35]

Multimodal Treatment: Patients selected for surgery differ systematically from those who are not, so observational comparisons of operated and unoperated patients cannot separate the effect of the operation from the effect of selection. In the MARS 2 randomised trial of 335 participants with resectable pleural mesothelioma, median survival was shorter in the surgery and chemotherapy group (19.3 months) than in the chemotherapy alone group (24.8 months).[52]

Access to Systemic Therapy: In CheckMate 743, first-line nivolumab plus ipilimumab produced median overall survival of 18.1 months versus 14.1 months for platinum-pemetrexed chemotherapy, and at three years 28% of responders on immunotherapy had an ongoing response versus 0% on chemotherapy.[53][1][24] Objective response rates were similar between the arms (40% versus 44%), so the difference lies in how long responses last rather than in how often patients respond.[24]

Clinical Trial Enrollment: Trial participants receive protocol-driven treatment with structured monitoring, and trials remain the main route to therapies not yet in standard practice.[54][55] Trial results should be read against their design. CheckMate 743 was randomised but enrolled only ECOG PS 0–1 patients.[1] The STELLAR trial of tumour treating fields was single-arm with no control group.[27] The 2025 ASCO guideline found insufficient evidence to make a recommendation on adding TTFields to pemetrexed plus platinum-based chemotherapy.[39]

Maintaining Performance Status: Poor performance status independently predicted shorter survival in the EORTC analysis,[7] was the most important prognostic split in the CALGB derivation,[16] and remained significant on multivariate analysis in the PLECH cohort (ECOG ≥2).[6]

Who Are Long-Term Mesothelioma Survivors?

Long-term survival in mesothelioma is generally defined as surviving 5 or more years after diagnosis.[56]

Characteristics of Long-Term Survivors

Analysis of published case series and National Cancer Database data reveals consistent patterns among mesothelioma long-term survivors:[56][10]

  • Younger age: Median survival of 59 months for patients aged 18–44 in the National Mesothelioma Virtual Bank cohort[10]
  • Female gender: Independent predictor of improved survival (HR 0.78)[13]
  • Epithelioid histology: Predominates among long-term survivors[4]
  • Complete macroscopic resection (MCR): Completeness of resection is the operative variable most strongly associated with long-term survival. In peritoneal disease it is scored as CC-0, meaning no visible residual tumour — median survival 104 months with CC-0 versus 30 months with CC-1 in a single-centre Australian series[15]
  • BAP1 germline mutation carriers: 47% five-year survival with molecularly favorable disease biology[5]

In a NCDB analysis of 3,636 peritoneal mesothelioma patients, 17.8% qualified as long-term survivors with a median survival of approximately 92 months.[56]

How Does Age Affect Mesothelioma Prognosis?

Age at diagnosis is an independent predictor of mesothelioma survival. In a U.S. cohort of 888 pleural and peritoneal patients, the hazard of death rose with each older age band.[10]

Age at Diagnosis Hazard Ratio for Death (95% CI), vs. Ages 18–44
18–44 1.00 (reference)
45–54 2.0 (1.3–3.0)
55–64 2.3 (1.6–3.3)
65–74 2.7 (1.8–3.9)
75+ 3.4 (2.3–5.1)

Source: National Mesothelioma Virtual Bank cohort, 888 patients[10]

Median survival was 59 months for patients aged 18–44 but 10 months for those 75 and older.[10] This disparity reflects both disease biology — younger patients more frequently have BAP1-associated disease and peritoneal location — and the ability to tolerate aggressive multimodal treatment including surgery.[57][58]

Young-onset mesothelioma (under 40) presents differently from disease diagnosed at older ages: peritoneal location is more common than pleural, particularly in young women, and germline BAP1 alterations are identified more frequently in this age group than in older patients. These are observed features of the young-onset population as a whole and do not speak to the cause of any individual case.[57][48]

⚠ Important: Regardless of prognosis, statutes of limitations for mesothelioma lawsuits typically range from 1 to 6 years from diagnosis and do not pause based on treatment outcomes. Even patients with favorable prognostic profiles should consult with experienced mesothelioma attorneys promptly to preserve all legal options.[59][60]

Frequently Asked Questions

What is the average prognosis for mesothelioma?

The average mesothelioma prognosis depends heavily on disease type, stage, and treatment. For pleural mesothelioma, median overall survival in the U.S. National Cancer Database was 10.3 months from diagnosis.[3] Peritoneal mesothelioma treated with CRS/HIPEC can achieve median survival exceeding 50 months. Individual prognosis may differ significantly from averages based on the prognostic factors described on this page.[2][15]

What is BAP1 and how does it affect prognosis?

BAP1 is a tumor suppressor gene. Patients carrying inherited (germline) BAP1 mutations develop a molecularly distinct form of mesothelioma with a substantially better prognosis — median survival of 5 years compared with less than 1 year in unselected SEER population controls. These patients show enhanced sensitivity to platinum-based chemotherapy and are more likely to survive long-term.[5][45] Somatic BAP1 loss, which occurs in tumour tissue only and is far more common, does not carry the same prognostic weight.[9]

What is the PLECH score?

PLECH is the newest validated mesothelioma prognostic scoring system (2025), using five weighted variables: Platelet count, LDH, ECOG performance status, Chest pain, and non-epithelioid Histology. Scores range from 0 to 7, with scores below 3 (low risk) predicting 20.1 months median survival versus 12.3 months for scores of 3 or higher. It outperforms both the CALGB and EORTC scores in predicting 1-year overall survival.[6]

Does gender affect mesothelioma prognosis?

Women with mesothelioma demonstrate approximately 50% better survival than men, with a hazard ratio of 0.78 for death and 5-year survival of 13.4% versus 4.5%. This difference may reflect hormonal factors, different exposure patterns (secondary versus occupational exposure), higher rates of epithelioid histology in women, and potentially different disease biology.[13][61]

How does the neutrophil-to-lymphocyte ratio predict outcomes?

The NLR is a simple blood test ratio. In a meta-analysis of 11 studies with 1,533 patients, an elevated NLR was associated with poorer overall survival (HR 1.48, 95% CI 1.16–1.89).[14]

Does treatment at a specialized center improve prognosis?

Research demonstrates that treatment at high-volume mesothelioma centers is associated with shorter hospitalization, lower readmission rates (4.6% vs. 6.1%), and lower 90-day mortality (10.0% vs. 14.6%). NCI-designated cancer centers with dedicated mesothelioma programs provide access to clinical trials, multidisciplinary teams, and high surgical volumes that improve outcomes.[17][35]

Should mesothelioma patients get germline genetic testing for BAP1?

Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and germline testing for patients with mesothelioma, particularly those diagnosed at younger ages and those with a family history of mesothelioma or related cancers.[48][57] Germline BAP1 status has implications for prognosis, treatment planning, and surveillance of blood relatives. This is distinct from somatic BAP1 testing of tumour tissue, which is routine in mesothelioma diagnosis but has no established prognostic or predictive value in current practice.[9]

Quick Statistics

  • 10.3 months median overall survival from diagnosis for pleural mesothelioma, 41,074 U.S. patients (National Cancer Database, 2004–2020)[3]
  • 5 years median survival for mesothelioma patients with germline BAP1 mutations versus less than 1 year for unselected SEER population controls[5]
  • 47% five-year survival rate among germline BAP1 mutation carriers compared to 6.7% in SEER population controls[5]
  • 59 months median survival for patients aged 18–44 versus 10 months for those 75 and older[10]
  • 13.4% five-year survival for women versus 4.5% for men — women have 22% lower mortality risk[13]
  • 104 months median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC in a single-centre Australian series of 81 patients[15]
  • 0.70 AUC achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model[6]
  • Elevated hazard ratio for death when neutrophil-to-lymphocyte ratio is high, with significantly reduced survival rates[14]
  • 10.0% vs. 14.6% 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers[17]

Medical Information:

Quick Reference:

Legal Resources:

Medically reviewed by Dr. Luciano Mutti, MD, PhD — Professor of Oncology, UniCamillus, Rome · Medical Oncology
Last reviewed: 2026-08-29 · Medical review covers clinical accuracy only and is not an endorsement of any legal service. See Editorial Standards for our editorial process.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, Baas P, Scherpereel A, et al. Lancet 2021 (PMID 33485464)
  2. ↑ 2.0 2.1 Mesothelioma Diagnosis Guide, Danziger & De Llano
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database, Bou-Samra P et al., Cancer Med, 2023. PMID 37062067.
  4. ↑ 4.0 4.1 4.2 4.3 Determinants of Survival in Malignant Pleural Mesothelioma: A SEER Study of 14,228 Patients, PLOS ONE, 2015
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015;36(1):76-81. PMID 25380601.
  6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 6.14 6.15 6.16 Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score, Oncology, 2025
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, Journal of Clinical Oncology, 1998
  8. ↑ Mesothelioma Compensation, Danziger & De Llano
  9. ↑ 9.0 9.1 9.2 9.3 Cedres S, Valdivia A, Priano I, et al. BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives. Cancers (Basel) 2025;17(9):1581. PMID 40361508.
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 Amin W, Linkov F, Landsittel DP, et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Research 2018. PMID 30410729.
  11. ↑ Epithelial Mesothelioma, MesotheliomaAttorney.com
  12. ↑ Sarcomatoid Mesothelioma Guide, MesotheliomaAttorney.com
  13. ↑ 13.0 13.1 13.2 13.3 Women with Malignant Pleural Mesothelioma Have a Threefold Better Survival Rate Than Men, Annals of Thoracic Surgery, 2014
  14. ↑ 14.0 14.1 14.2 14.3 Chen N, Liu S, Huang L, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis. Oncotarget 2017;8(34):57460-57469. PMID 28915685.
  15. ↑ 15.0 15.1 15.2 15.3 Shamavonian R, Cheng E, Karpes JB, et al. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre. Anticancer Res. 2022;42(6):2939-2944. PMID 35641285
  16. ↑ 16.0 16.1 16.2 Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998. PMID 9515850.
  17. ↑ 17.0 17.1 17.2 17.3 Verma V, Ahern CA, Berlind CG, et al. Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis. Lung Cancer 2018. PMID 29748018.
  18. ↑ 18.0 18.1 18.2 Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center, Valenzuela CD et al., Ann Surg Oncol, 2023. PMID 36754945.
  19. ↑ 19.0 19.1 Life Expectancy in Pleural and Peritoneal Mesothelioma, Shavelle R et al., Lung Cancer Int, 2017. PMID 28239496.
  20. ↑ 20.0 20.1 20.2 Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study, van Kooten JP et al., Thorax, 2022. PMID 35149582.
  21. ↑ 21.0 21.1 Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival, Beebe-Dimmer JL et al., Clin Epidemiol, 2016. PMID 27822122.
  22. ↑ 22.0 22.1 Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma, Alexander HR Jr et al., Surgery, 2013. PMID 23489943.
  23. ↑ Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, Vogelzang NJ et al., J Clin Oncol, 2003. PMID 12860938.
  24. ↑ 24.0 24.1 24.2 24.3 Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33(5):488-499. PMID 35124183.
  25. ↑ 25.0 25.1 25.2 Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743, Scherpereel A, Baas P, et al. Journal of Clinical Oncology 2026 (PMID 41734361) — 5-year OS 14% vs. 6%
  26. ↑ FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma, Nakajima EC et al., Clin Cancer Res, 2022. PMID 34462287.
  27. ↑ 27.0 27.1 Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019;20(12):1702-1709. PMID 31628016.
  28. ↑ Malignant Mesothelioma, Danziger & De Llano
  29. ↑ Mesothelioma Treatment (PDQ) — Patient Version, National Cancer Institute
  30. ↑ 30.0 30.1 Stages of Mesothelioma, Mesothelioma Lawyer Center
  31. ↑ Peritoneal Mesothelioma Cancer, Mesothelioma Lawyer Center
  32. ↑ 32.0 32.1 32.2 32.3 32.4 32.5 A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis, Journal of Thoracic Oncology, 2016
  33. ↑ Mesothelioma Treatment Centers, Mesothelioma.net
  34. ↑ 34.0 34.1 Top-Rated Mesothelioma Lawyers, Danziger & De Llano
  35. ↑ 35.0 35.1 35.2 NCI-Designated Cancer Centers, National Cancer Institute
  36. ↑ Steele JP, Klabatsa A, Fennell DA, et al. Prognostic factors in mesothelioma. Lung Cancer 2005. PMID 15894403.
  37. ↑ 37.0 37.1 BTS Guideline for the Investigation and Management of Pleural Mesothelioma, British Thoracic Society, 2018
  38. ↑ 38.0 38.1 Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma, Wang T, Li H, Ye B, Zhang D. American Journal of Translational Research 2021;13(9):10712–10720. PMID 34650746
  39. ↑ 39.0 39.1 Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol 2025;43(8):1006-1038. PMID 39778125.
  40. ↑ Belli C, Gray SG, Masedu F, Mutti L. Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743. J Clin Oncol 2026. PMID 42430689.
  41. ↑ Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines, Panou V, Sørensen JB, Ravn J, Santoni-Rugiu E. European Clinical Respiratory Journal 2025;12(1):2580795 (PMID 41179988)
  42. ↑ Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000. PMID 10950889.
  43. ↑ Mesothelioma Life Expectancy and Survival Rate, Mesothelioma.net
  44. ↑ Pleural vs Peritoneal Mesothelioma Differences, Danziger & De Llano
  45. ↑ 45.0 45.1 Inherited Predisposition to Malignant Mesothelioma and Overall Survival Following Platinum Chemotherapy, Proceedings of the National Academy of Sciences, 2019
  46. ↑ 46.0 46.1 Medical and Surgical Care of Mesothelioma Patients and Their Relatives Carrying Germline BAP1 Mutations, Journal of Thoracic Oncology, 2022
  47. ↑ 47.0 47.1 47.2 47.3 47.4 47.5 Carbone M, Minaai M, Kittaneh M, et al. Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. J Thorac Oncol 2025;20(11):1683-1698. PMID 40582407.
  48. ↑ 48.0 48.1 48.2 48.3 Clinical Practice Guidelines for the Diagnosis and Surveillance of BAP1 Tumor Predisposition Syndrome, European Journal of Human Genetics, 2023
  49. ↑ Wu X, Hernandez FV, Wang H, et al. Prospective Analysis of Mesotheliomas in Subjects With BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease. J Thorac Oncol 2025;20(11):1699-1715. PMID 40774608.
  50. ↑ Mesothelioma Treatment Guide, Mesothelioma Lawyer Center
  51. ↑ Survival Rates for Pleural Mesothelioma, American Cancer Society
  52. ↑ Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med 2024. PMID 38740044.
  53. ↑ FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma, U.S. Food and Drug Administration, 2020
  54. ↑ Mesothelioma Clinical Trials, ClinicalTrials.gov
  55. ↑ Mesothelioma, Mesothelioma Lawyer Center
  56. ↑ 56.0 56.1 56.2 Bhatt H, Vakil DP, Quintero L, et al. Characteristics of Long-Term Survivors With Peritoneal Mesothelioma - Insights From the National Cancer Database. The American Surgeon 2026;92(1):53-61 (published online 17 June 2025). PMID 40525260.
  57. ↑ 57.0 57.1 57.2 Case Report: Mesothelioma and BAP1 Tumor Predisposition Syndrome, Frontiers in Oncology, 2022
  58. ↑ Pleural Mesothelioma, MesotheliomaAttorney.com
  59. ↑ What's Your Mesothelioma Case Worth?, Danziger & De Llano
  60. ↑ Mesothelioma Compensation Guide, MesotheliomaAttorney.com
  61. ↑ Study Shows Higher Mesothelioma Survival Rates in Women, Mesothelioma Lawyer Center
  62. ↑ Asbestos & Mesothelioma Lawyers, Danziger & De Llano
  63. ↑ Find Top Mesothelioma Attorneys, Mesothelioma Lawyer Center


Retrieved from "https://wikimesothelioma.com/w/index.php?title=Mesothelioma_Prognosis&oldid=5016"